Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy.
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy.
复制标题
DOI：
10.2217/imt.09.21
复制
发表时间：
2009-07
期刊：
影响因子：
2.8
通讯作者：
Mellor AL
中科院分区：
文献类型：
--
作者：
Johnson BA 3rd;Baban B;Mellor AL
Natural immune tolerance is a formidable barrier to successful immunotherapy to treat established cancers and chronic infections. Conversely, creating robust immune tolerance via immunotherapy is the major goal in treating autoimmune and allergic diseases, and enhancing survival of transplanted organs and tissues. In this review, we focus on a natural mechanism that creates local T-cell tolerance in many clinically relevant settings of chronic inflammation involving expression of the cytosolic enzyme indoleamine 2,3-dioxygenase (IDO) by specialized subsets of dendritic cells. IDO-expressing dendritic cells suppress antigen-specific T-cell responses directly, and induce bystander suppression by activating regulatory T cells. Thus, manipulating IDO is a promising strategy to treat a range of chronic inflammatory diseases.
